Relmada regains Nasdaq minimum bid price compliance; stock remains listed on Capital Market

RELMADA THERAPEUTICS, INC.

Received Nasdaq written notice on Sept 15, 2025, confirming compliance with $1.00 minimum bid price rule after 10 consecutive trading days.
Compliance achieved after closing bid price exceeded $1.00 from Aug 29 to Sept 12, 2025; Nasdaq considers matter closed.
Relmada now fully compliant with all Nasdaq continued listing requirements; RLMD remains traded on Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.